Cellective BioTherapy
Cellective BioTherapy: Pioneering B cell-based therapies for personalized cancer treatment since 2015.
Founded
2015Cellective BioTherapy: Pioneering B cell-based therapies for personalized cancer treatment since 2015.
Cellective BioTherapy, Inc. was founded in 2015 with a core mission to develop innovative antibody and cell-based therapies utilizing regulatory B (B10) cells. The company's vision is to revolutionize personalized medicine by enhancing patients' immune responses against tumors and creating tailored cellular treatments for a variety of diseases. Their primary focus is on harnessing the unique properties of B10 cells to both boost immunity and provide targeted therapeutic solutions in the oncology sector.
Notable figures associated with Cellective BioTherapy include leading scientists and industry experts in immunology and biotechnology. The company has attracted significant investment from prominent venture capital firms specializing in life sciences. Key achievements include pioneering research in B cell immunotherapy and advancing several promising candidates through preclinical development stages. Cellective BioTherapy's work has had a substantial impact on the field of personalized cancer treatment, positioning them as a leader in the development of next-generation immunotherapies.
Companies similar to Cellective BioTherapy include Be Biopharma, Bespoke Biotherapeutics, Cellerant Therapeutics and Immpact Bio.
Cellective BioTherapy was founded in 2015.
Cellective BioTherapy's headquarters is located in Durham, NC, US.
Cellective BioTherapy's most recent funding round was for $2.5M (USD) in June 2015.
As of Jun 12, 2015, Cellective BioTherapy has disclosed funding of $2.5M (USD). Undisclosed round amounts are excluded.
Cellective BioTherapy has 7 employees as of Feb 5, 2024.
Immpact Bio
immpact-bio.com
